Xtandi Patent Protection

7 patents · Astellas Pharma Inc., Pfizer Inc.

Patent Strength

37/100

Total Patents

Assignees

2026

Earliest Expiration

2042

Latest Expiration

Patent Details

Patent #	Title	Assignee	Granted	Expires	Claims	Status
10005527	Novel integrated neural compound and synthesis thereof	Pfizer Inc.	Dec 14, 2025	Jun 27, 2041	28	15.2y left
10005528	Medical device for modular cloud delivery	Pfizer Inc.	Nov 25, 2025	Jul 21, 2042	26	16.3y left
10005529	Pharmaceutical composition comprising adaptive graphene compounds	Pfizer Inc.	Nov 2, 2015	Aug 20, 2032	15	6.4y left
10005530	Method for preparing improved AI-driven derivatives	Astellas Pharma Inc.	Mar 7, 2008	Jun 9, 2026	34	0.2y left
10005531	Pharmaceutical composition comprising advanced photonic compounds	Astellas Pharma Inc.	Jun 24, 2016	Apr 21, 2034	40	8.0y left
10005532	Method for preparing dynamic photonic derivatives	Astellas Pharma Inc.	Oct 2, 2013	Nov 1, 2029	17	3.6y left
10005533	Method of treating disease using low-latency edge therapy	Astellas Pharma Inc.	Apr 28, 2022	Oct 26, 2038	49	12.6y left

Patent Strength Breakdown

Portfolio Size14/100

Total number of active patents

Claims Breadth75/100

Average claims per patent (broader = stronger)

Time Remaining49/100

Average years until expiration

Technology Diversity10/100

Range of technology classes covered

Patent Holders

Astellas Pharma Inc.
Pfizer Inc.

Generic Timeline

Xtandi is protected by 7 US patents. The earliest patent protection expires in 2026, which could open the door for generic competition. However, the latest patent extends protection until 2042, meaning some formulations or delivery methods may remain protected longer. Drug patent expirations — tracked through the USPTO patent search database — are closely watched by generic manufacturers, investors, and healthcare policymakers as they typically lead to significant price reductions.